Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11986360 | 0.83 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11612722 | 0.83 | CA12 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25074911 | 0.81 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3511274 | 0.81 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11986364 | 0.80 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9517356 | 0.79 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL920631 | 0.79 | AR (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9914231 | 0.78 | ACHE (0.58) | ALDH1A1CYP3A4MEN1KMT2ALMNA | |
| SCHEMBL6604093 | 0.78 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3640883 | 0.78 | ALDH1A1 (0.61) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116745286-A | Novel galectin inhibitors of galectins | 格莱克特生物技术公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-109661394-A | FGFR4 inhibitor, preparation method and application pharmaceutically | 上海和誉生物医药科技有限公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-109476672-A | NOVEL HETEROCYCLIC DERIVATIVE COMPOUND AND USE THEREOF | 韩美药品株式会社 | 2019-03-15 | — | — | CN | disclosed |
| CN-109384790-A | Fibroblast growth factor acceptor inhibitor and application thereof | 南京药捷安康生物科技有限公司 | 2019-02-26 | — | — | CN | disclosed |
| CN-107922410-A | Methods for making FGFR inhibitors | 普林斯匹亚生物制药公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-106459034-B | Carbostyril derivative as fibroblast growth factor acceptor inhibitor | 普林斯匹亚生物制药公司 | 2018-01-12 | — | — | CN | disclosed |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-05-25 | — | — | US | disclosed |
| CN-106459034-A | Quinolone derivatives as fibroblast growth factor receptor inhibitors | 普林斯匹亚生物制药公司 | 2017-02-22 | — | — | CN | disclosed |
| US-8916071-B2 | Chromene compound and curable composition | TOKUYAMA CORPORATION (JP) | 2014-12-23 | — | — | US | disclosed |
| US-20140225050-A1 | CHROMENE COMPOUND AND CURABLE COMPOSITION | TOKUYAMA CORPORATION (JP) | 2014-08-14 | — | — | US | disclosed |
| US-20100286169-A1 | Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRDT, BRD3 | CA12 4738/4885CA1 4702/4885CA2 4594/4885 |
| US-20100286169-A1 | Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds | TST, UMPS, UROD | CA12 4265/4885CA1 4273/4885CA2 4417/4885 |
| US-20140225050-A1 | CHROMENE COMPOUND AND CURABLE COMPOSITION | CRY2, CRY1, CDYL | CA12 2301/4885CA1 3137/4885CA2 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.